Denosumab Densitometric Changes Assessed by Quantitative Computed Tomography at the Spine and Hip in Postmenopausal Women With Osteoporosis
Michael R. McClung(Bone Health and Osteoporosis Foundation), Cesar Libanati(Amgen (United States)), José Zanchetta(Universidad del Salvador), Edward Franek(Mossakowski Medical Research Institute, Polish Academy of Sciences), Jacques P. Brown(Centre hospitalier de l'Université Laval), Michael A. Bolognese, Sigitas Stonkus(Klaipėda University), Chris Recknor(Bone Health and Osteoporosis Foundation), Maria Luisa Brandi(Vita-Salute San Raffaele University), Andrea Wang(Amgen (United States)), Chui Kin Yuen(University of British Columbia), Stefan Goemaere(Ghent University Hospital), Arne Høiseth, Grattan C. Woodson, David L. Kendler(University of British Columbia)
Cited by 33
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
|The Lancet|2019|3.1k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
|Osteoporosis International|2007|1.2k